Cargando…

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre

BACKGROUND: Recent evidence suggests that higher rifampicin doses may improve tuberculosis (TB) treatment outcome. METHODS: In this observational cohort study we evaluated all TB patients who were treated with high-dose rifampicin (> 10 mg/kg daily) in our reference centre, from January 2008 to M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seijger, Charlotte, Hoefsloot, Wouter, Bergsma-de Guchteneire, Inge, te Brake, Lindsey, van Ingen, Jakko, Kuipers, Saskia, van Crevel, Reinout, Aarnoutse, Rob, Boeree, Martin, Magis-Escurra, Cecile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417786/ https://www.ncbi.nlm.nih.gov/pubmed/30870476 http://dx.doi.org/10.1371/journal.pone.0213718

Ejemplares similares

New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
por: Aguilar Diaz, Jessica M, et al.
Publicado: (2023)

Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
por: Zweijpfenning, Sanne M.H., et al.
Publicado: (2021)

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: te Brake, Lindsey H. M., et al.
Publicado: (2019)

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
por: Litjens, Carlijn H. C., et al.
Publicado: (2021)

The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease
por: Schildkraut, Jodie A., et al.
Publicado: (2023)

The Antipsychotic Thioridazine Shows Promising Therapeutic Activity in a Mouse Model of Multidrug-Resistant Tuberculosis
por: van Soolingen, Dick, et al.
Publicado: (2010)

Mycobacterium xenopi Clinical Relevance and Determinants, the Netherlands
por: van Ingen, Jakko, et al.
Publicado: (2008)

Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients
por: te Brake, Lindsey H.M., et al.
Publicado: (2018)

Epidemiology of Mycobacterium bovis Disease in Humans, the Netherlands, 1993–2007
por: Majoor, Christof J., et al.
Publicado: (2011)

Immune defects in patients with pulmonary Mycobacterium abscessus disease without cystic fibrosis
por: Schuurbiers, Milou M.F., et al.
Publicado: (2020)

Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials
por: Svensson, Elin M, et al.
Publicado: (2019)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
por: Stemkens, Ralf, et al.
Publicado: (2023)

Characterization of Mycobacterium orygis as M. tuberculosis Complex Subspecies
por: van Ingen, Jakko, et al.
Publicado: (2012)

Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease
por: Danho, Rabi, et al.
Publicado: (2022)

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance
por: Martinecz, Antal, et al.
Publicado: (2023)

Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania
por: Ruesen, Carolien, et al.
Publicado: (2018)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
por: Svensson, Elin M, et al.
Publicado: (2018)

Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

The accuracy of an electronic nose to diagnose tuberculosis in patients referred to an expert centre
por: Coronel Teixeira, Rosarito, et al.
Publicado: (2023)

Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study
por: Soeroto, Arto Yuwono, et al.
Publicado: (2019)

Subtle immunodeficiencies in nodular–bronchiectatic Mycobacterium avium complex lung disease
por: Bruno, Mariolina, et al.
Publicado: (2020)

The Interaction of Diabetes and Tuberculosis: Translating Research to Policy and Practice
por: van Crevel, Reinout, et al.
Publicado: (2021)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial
por: Espinosa-Pereiro, Juan, et al.
Publicado: (2022)

Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study
por: Ghimire, Samiksha, et al.
Publicado: (2023)

Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis
por: Saktiawati, Antonia Morita I., et al.
Publicado: (2019)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Current Methods in the Molecular Typing of Mycobacterium tuberculosis and Other Mycobacteria
por: Jagielski, Tomasz, et al.
Publicado: (2014)

Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
por: Susanto, Budi O, et al.
Publicado: (2019)

Immunologic, metabolic and genetic impact of diabetes on tuberculosis susceptibility
por: Ssekamatte, Phillip, et al.
Publicado: (2023)

Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
por: Zhang, Zehua, et al.
Publicado: (2014)

Innate Immune Recognition of Mycobacterium tuberculosis
por: Kleinnijenhuis, Johanneke, et al.
Publicado: (2011)

Otomastoiditis Caused by Mycobacterium abscessus, the Netherlands
por: van Ingen, Jakko, et al.
Publicado: (2010)

Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management
por: Prasad, Rajendra, et al.
Publicado: (2018)

Pyrazinamide resistance in rifampicin discordant tuberculosis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2022)

Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
por: Cai, Xingshan, et al.
Publicado: (2022)

SNP/RD Typing of Mycobacterium tuberculosis Beijing Strains Reveals Local and Worldwide Disseminated Clonal Complexes
por: Schürch, Anita C., et al.
Publicado: (2011)

Perspective for Precision Medicine for Tuberculosis
por: Lange, Christoph, et al.
Publicado: (2020)

Efficacy and role of Xpert(®) Mycobacterium tuberculosis/rifampicin assay in urinary tuberculosis
por: Samuel, Benedict Paul, et al.
Publicado: (2018)

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r3avoi5fr5hcde1v1jum1j9laq